Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28646026 | 0.88 | ALDH1A1 (0.44) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL2594514 | 0.87 | ALDH1A1 (0.48) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL15110981 | 0.85 | ALDH1A1 (0.47) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL4721794 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7618086 | 0.84 | MEN1 (0.46) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL15111012 | 0.84 | ALDH1A1 (0.46) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL7406263 | 0.84 | ALDH1A1 (0.49) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL14825340 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2KMT2AALDH1A1MAPTNPC1 | |
| SCHEMBL6121694 | 0.83 | MEN1 (0.51) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT | |
| SCHEMBL21594910 | 0.83 | MEN1 (0.65) | SMN1; SMN2KMT2AALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-4144728-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | Shanghaitech University (CN) | 2023-03-08 | — | — | EP | disclosed |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2022-05-12 | — | — | US | disclosed |
| EP-3932922-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | ShanghaiTech University (CN) | 2022-01-05 | — | — | EP | disclosed |
| WO-2021219078-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | 上海科技大学 (CN) | 2021-11-04 | — | — | WO | disclosed |
| US-6867305-B2 | Synthesis of epothilones, intermediates thereto and analogues thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2005-03-15 | — | — | US | disclosed |
| WO-2005000781-A1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | HOFFMANN-LA ROCHE AG | 2004-12-30 | — | — | US | disclosed |
| US-20020058286-A1 | Synthesis of epothilones, intermediates thereto and analogues thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-16 | — | — | US | disclosed |
| US-20020058817-A1 | Synthesis of epothilones, intermediates thereto and analogues thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-16 | — | — | US | disclosed |
| EP-0734386-B1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LAB (US) | 2002-02-06 | — | — | EP | disclosed |
| US-6160012-A | Leukotriene B4 derivatives, in particular oximo-LTB4 - antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-12 | — | — | US | disclosed |
| EP-0734386-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | Abbott Laboratories (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5486525-A | ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1996-01-23 | — | — | US | disclosed |
| WO-1995016687-A1 | PLATELET ACTIVATING FACTOR ANTAGONISTS: IMIDAZOPYRIDINE INDOLES | ABBOTT LABORATORIES (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266856-A1 | Biaryloxymethylarenecarboxylic acids as glycogen synthase activator | GYS2, GYS1, PYGL | SMN1; SMN2 1436/4885KMT2A 3431/4885ALDH1A1 414/4885 |
| US-20020058817-A1 | Synthesis of epothilones, intermediates thereto and analogues thereof | DHPS, PPOX, THPO | SMN1; SMN2 4511/4885KMT2A 1403/4885ALDH1A1 474/4885 |
| US-20230203022-A1 | HETEROCYCLE AND GLUTARIMIDE SKELETON-BASED COMPOUND AND APPLICATIONS THEREOF | TNF, GCDH, LITAF | SMN1; SMN2 2290/4885KMT2A 3871/4885ALDH1A1 568/4885 |
| US-20220411402-A1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CYP3A7, CYP3A4, CYP3A43 | SMN1; SMN2 3696/4885KMT2A 4025/4885ALDH1A1 1096/4885 |
| US-11414399-B2 | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CYP3A7, CYP3A4, CYP3A43 | SMN1; SMN2 3696/4885KMT2A 4025/4885ALDH1A1 1096/4885 |
| US-20220143002-A1 | SULFUR-CONTAINING COMPOUND BASED ON GLUTARIMIDE SKELETON AND APPLICATION THEREOF | GLS, SQOR, GCDH | SMN1; SMN2 945/4885KMT2A 3279/4885ALDH1A1 958/4885 |
| US-20020058286-A1 | Synthesis of epothilones, intermediates thereto and analogues thereof | DHPS, PPOX, THPO | SMN1; SMN2 4511/4885KMT2A 1403/4885ALDH1A1 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.